Srdan Verstovsek, M.D., Ph.D.

Peer-Reviewed Articles

1. Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali KH, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon S-S, Gupta V, Kiladjian J-J, Granacher N, Lee S-E, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R, on behalf of the MOMENTUM Study Investigators. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): Results from an international, double-blind, randomised, controlled phase 3 study. The Lancet 401(10373):269-280, 2023. e-Pub 2023.
2. Passamonti F, Harrison CN, Mesa RA, Kiladjian JJ, Vannucchi AM, Verstovsek S. Anemia in myelofibrosis: current and emerging treatment options. Crit Rev Oncol Hematol 180:103862, 2022. e-Pub 2022. PMID: 36332787.
3. Verstovsek S, Al-Ali HK, Mascarenhas J, Perkins A, Vannucchi AM, Mohan SR, Scott BL, Woszczyk D, Koschmieder S, García-Delgado R, László R, McGreivy JS, Rothbaum WP, Kiladjian JJ. BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis. Future Oncol, 2022. e-Pub 2022. PMID: 36416118.
4. Mascarenhas J, Gleitz HFE, Chifotides HT, Harrison CN, Verstovsek S, Vannucchi AM, Rampal RK, Kiladjian JJ, Vainchenker W, Hoffman R, Schneider RK, List AF. Biological drivers of clinical phenotype in myelofibrosis. Leukemia 37:255-264, 2022. e-Pub 2022. PMID: 36434065.
5. Krecak I, Lucijanic M, Verstovsek S. Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia. Curr Hematol Malig Rep 17(5):155-169, 2022. e-Pub 2022. PMID: 35932395.
6. Guglielmelli P, Kiladjian JJ, Vannucchi AM, Duan M, Meng H, Pan L, He G, Verstovsek S, Boyer F, Barraco F, Niederwieser D, Pungolino E, Liberati AM, Harrison C, Roussou P, Wroclawska M, Karumanchi D, Sinclair K, Te Boekhorst PAW, Gisslinger H. Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50×10^9/L to <100×10^9/L) at baseline: the final analysis of EXPAND. Ther Adv Hematol 13:20406207221118429, 2022. e-Pub 2022. PMID: 36105914.
7. Verstovsek S, Komatsu N, Gill H, Jin J, Lee SE, Hou HA, Sato T, Qin A, Urbanski R, Shih W, Zagrijtschuk O, Zimmerman C, Mesa RA. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia. Future Oncol 18(27):2999-3009, 2022. e-Pub 2022. PMID: 35924546.
8. Harrison CN, Gupta VK, Gerds AT, Rampal R, Verstovsek S, Talpaz M, Kiladjian JJ, Mesa R, Kuykendall AT, Vannucchi AM, Palandri F, Grosicki S, Devos T, Jourdan E, Wondergem MJ, Al-Ali HK, Buxhofer-Ausch V, Alvarez-Larrán A, Patriarca A, Kremyanskaya M, Mead AJ, Akhani S, Sheikine Y, Colak G, Mascarenhas J. Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. Future Oncol 18(27):2987-2997, 2022. e-Pub 2022. PMID: 35950489.
9. Verstovsek S, Mesa R, Talpaz M, Kiladjian JJ, Harrison CN, Oh ST, Vannucchi AM, Rampal R, Scott BL, Buckley SA, Craig AR, Roman-Torres K, Mascarenhas JO. Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia. Haematologica 107(7):1599-1607, 2022. e-Pub 2022. PMID: 34551507.
10. Mesa R, Harrison C, Oh ST, Gerds AT, Gupta V, Catalano J, Cervantes F, Devos T, Hus M, Kiladjian JJ, Lech-Maranda E, McLornan D, Vannucchi AM, Platzbecker U, Huang M, Strouse B, Klencke B, Verstovsek S. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. Leukemia 36(9):2261-2268, 2022. e-Pub 2022. PMID: 35869266.
11. El Hussein S, Chifotides HT, Khoury JD, Verstovsek S, Thakral B. Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update. Cancers (Basel) 14(14):3474, 2022. e-Pub 2022. PMID: 35884535.
12. Mascarenhas JO, Verstovsek S. The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes. Cancer 128(14):2717-2727, 2022. e-Pub 2022. PMID: 35385124.
13. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The 5^th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 36(7):1703-1719, 2022. e-Pub 2022. PMID: 35732831.
14. Kosiorek HE, Scherber RM, Geyer HL, Verstovsek S, Langlais BT, Mazza GL, Gotlib J, Gupta V, Padrnos LJ, Palmer JM, Fleischman A, Mesa RA, Dueck AC. Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)-I study. Br J Haematol 198(6):1065-1068, 2022. e-Pub 2022. PMID: 35751150.
15. Verstovsek S. Cases in the management of polycythemia vera: switching from hydroxyurea to ruxolitinib to resolve symptoms and improve quality of life. Clin Adv Hematol Oncol 20 Suppl 11(6):1-12, 2022. PMID: 35772008.
16. Pemmaraju N, Verstovsek S, Mesa R, Gupta V, Garcia JS, Scandura JM, Oh ST, Passamonti F, Döhner K, Mead AJ. Defining disease modification in myelofibrosis in the era of targeted therapy. Cancer 128(13):2420-2432, 2022. e-Pub 2022. PMID: 35499819.
17. Mascarenhas J, Harrison CN, Kiladjian JJ, Komrokji RS, Koschmieder S, Vannucchi AM, Berry T, Redding D, Sherman L, Dougherty S, Peng L, Sun L, Huang F, Wan Y, Feller FM, Rizo A, Verstovsek S. Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design. Future Oncol 18(22):2393-2402, 2022. e-Pub 2022. PMID: 35510486.
18. Pemmaraju N, Garcia JS, Potluri J, Harb JG, Sun Y, Jung P, Qin QQ, Tantravahi SK, Verstovsek S, Harrison C. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study. Lancet Haematol 9(6):e434-e444, 2022. e-Pub 2022. PMID: 35576960.
19. Manshouri T, Veletic I, Li P, Yin CC, Post SM, Verstovsek S, Estrov Z. GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes. Cell Death Dis 13(5):481, 2022. e-Pub 2022. PMID: 35595725.
20. Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Zhang J, Sy O, Mesa RA. Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts. Br J Haematol 198(2):317-327, 2022. e-Pub 2022. PMID: 35476316.
21. Barrios-Ruiz A, Davila-Gonzalez D, Fountain E, Cheng L, Verstovsek S, Rojas-Hernandez CM. Potential limitations of diagnostic standard codes to distinguish polycythemia vera and secondary erythrocytosis. Sci Rep 12(1):4674, 2022. e-Pub 2022. PMID: 35304527.
22. Yilmaz M, Verstovsek S. Managing patients with myelofibrosis and thrombocytopenia. Expert Rev Hematol 15(3):233-241, 2022. e-Pub 2022. PMID: 35316110.
23. Mesa R, Oh ST, Gerds AT, Gupta V, Catalano J, Cervantes F, Devos T, Hus M, Kiladjian JJ, Lech-Maranda E, McLornan D, Palmer J, Platzbecker U, Trelinski J, Shimoda K, Donahue R, D'Hollander K, Kowalski M, Verstovsek S. Momelotinib reduces transfusion requirements in patients with myelofibrosis. Leuk Lymphoma 63(7):1718-1722, 2022. e-Pub 2022. PMID: 35255234.
24. Chifotides HT, Bose P, Masarova L, Pemmaraju N, Verstovsek S. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis. Clin Lymphoma Myeloma Leuk 22(4):210-223, 2022. e-Pub 2021. PMID: 34840087.
25. Harrison CN, Garcia JS, Somervaille TCP, Foran JM, Verstovsek S, Jamieson C, Mesa R, Ritchie EK, Tantravahi SK, Vachhani P, O'Connell CL, Komrokji RS, Harb J, Hutti JE, Holes L, Masud AA, Nuthalapati S, Potluri J, Pemmaraju N. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. J Clin Oncol 40(15):1671-1680, 2022. e-Pub 2022. PMID: 35180010.
26. Pemmaraju N, Gerds AT, Yu J, Parasuraman S, Shah A, Xi A, Kumar S, Scherber RM, Verstovsek S. Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia. Leuk Res 115:106809, 2022. e-Pub 2022. PMID: 35220060.
27. Gerds AT, Lyons RM, Colucci P, Kalafut P, Paranagama D, Verstovsek S. Disease and Clinical Characteristics of Patients with a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study. Clin Lymphoma Myeloma Leuk 22(7):e532-e540, 2022. e-Pub 2022. PMID: 35256316.
28. Gerds AT, Yu J, Scherber RM, Paranagama D, Kish JK, Visaria J, Singhal M, Verstovsek S, Pemmaraju N. Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes. Acta Haematol:1-5, 2022. e-Pub 2022. PMID: 35008087.
29. Chifotides HT, Bose P, Verstovsek S. Momelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol 15(1):7, 2022. e-Pub 2022. PMID: 35045875.
30. Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer 128(8):1658-1665, 2022. e-Pub 2022. PMID: 35077575.
31. Vachhani P, Verstovsek S, Bose P. Disease Modification in Myelofibrosis: An Elusive Goal?. J Clin Oncol 40(11):1147-1154, 2022. e-Pub 2022. PMID: 35084934.
32. DeAngelo DJ, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW, Bose P, Hexner EO, Winton EF, Horny HP, Tugnait M, Schmidt-Kittler O, Evans EK, Lin HM, Mar BG, Verstovsek S, Deininger MW, Gotlib J. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med 27(12):2183-2191, 2021. e-Pub 2021. PMID: 34873347.
33. Verstovsek S, Parasuraman S, Yu J, Shah A, Kumar S, Xi A, Harrison C. Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval. Ann Hematol 101(1):131-137, 2021. e-Pub 2021. PMID: 34625831.
34. Verstovsek S, Yu J, Scherber RM, Verma S, Dieyi C, Chen CC, Parasuraman S. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma 63(3):694-702, 2021. e-Pub 2021. PMID: 34689695.
35. Veletic I, Prijic S, Manshouri T, Nogueras_Gonzalez GM, Verstovsek S, Estrov Z. Altered T-Cell Subset Repertoire Affects Treatment Outcome Of Patients With Myelofibrosis. Haematologica 106(9):2384-2396, 2021. e-Pub 2021. PMID: 32732359.
36. Verstovsek S, Amoloja T, Scherber RM, Yu J. Real-world patient characteristics and treatment patterns of ruxolitinib among patients with advanced essential thrombocythemia at community clinical practice. Leuk Res 110:106711, 2021. e-Pub 2021. PMID: 34624568.
37. Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce, S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv 5(16):3163-3173, 2021. e-Pub 2021. PMID: 34424319.
38. Lee SS, Verstovsek S, Pemmaraju N. Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy. J Immunother Precis Oncol 4(3):117-128, 2021. e-Pub 2021. PMID: 35663101.
39. Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica 106(7):1988-1990, 2021. e-Pub 2021. PMID: 31296578.
40. Bose P, Verstovsek S. Avapritinib: an emerging new therapy for systemic mastocytosis. Expert Rev Hematol 14(8):687-696, 2021. e-Pub 2021. PMID: 34289787.
41. Bose P, Verstovsek S. SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis. Clin Lymphoma Myeloma Leuk 21(10):641-649, 2021. e-Pub 2021. PMID: 34272171.
42. Mesa RA, Schaap N, Vannucchi AM, Kiladjian JJ, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Abraham P, Lord-Bessen J, Tang D, Guo S, Ye X, Harrison CN. Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. HemaSphere 5(5):e553, 2021. e-Pub 2021. PMID: 33969273.
43. Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Jourdan E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Tang D, Abraham P, Lord-Bessen J, Rose S, Guo S, Liao W, Mesa RA. Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial. HemaSphere 5(5):e562, 2021. e-Pub 2021. PMID: 33969275.
44. Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J 11(5):98, 2021. e-Pub 2021. PMID: 34016956.
45. Verstovsek S, Chen CC, Egyed M, Ellis M, Fox L, Goh YT, Gupta V, Harrison C, Kiladjian JJ, Lazaroiu MC, Mead A, McLornan D, McMullin MF, Oh ST, Perkins A, Platzbecker U, Scheid C, Vannucchi A, Yoon SS, Kowalski MM, Mesa RA. MOMENTUM: Momelotinib versus Danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncol 17(12):1449-1458, 2021. e-Pub 2021. PMID: 33423550.
46. Pemmaraju N, Chen NC, Verstovsek S. Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms. Hematol Oncol Clin North Am 35(2):409-429, 2021. e-Pub 2021. PMID: 33641877.
47. Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Tariq Siddiqui M, Sasaki K, Wei Y, Yang H, Chien KS, Naqvi K, Jabbour E, Kadia TM, Daver N, DiNardo C, Ravandi F, Pemmaraju N, Bose P, Verstovsek S, Pierce S, Bueso-Ramos C, Patel K, Do KA, Kantarjian H, Garcia-Manero G. Clinical, Genomic, and Transcriptomic Differences between Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS). Am J Hematol 96(7):E246-E249, 2021. e-Pub 2021. PMID: 33811786.
48. Shah MV, Saliba RM, Verma A, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Masarova L, Alousi AM, Srour S, Mehta RS, Daver N, Pemmaraju N, Verstovsek S, Champlin RE, Popat UR. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol 193(5):1004-1008, 2021. e-Pub 2021. PMID: 33821472.
49. Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. PMID: 33792630.
50. Kadia TM, Ravandi F, Borthakur G, Konopleva M, DiNardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, Pierce S, Rausch C, Burger J, Ferrajoli A, Jain N, Popat U, Estrov Z, Verstovsek S, Jabbour E, Garcia-Manero G, Kantarjian H. Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol 96(8):914-924, 2021. e-Pub 2021. PMID: 33901324.
51. Masarova L, DiNardo CD, Bose P, Pemmaraju N, Daver NG, Kadia TM, Chifotides HT, Zhou L, Borthakur G, Estrov Z, Konopleva M, Verstovsek S. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv 5(8):2156-2164, 2021. e-Pub 2021. PMID: 33885751.
52. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer, 2021. e-Pub 2021. PMID: 33914911.
53. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov Z. STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget 12(5):401-411, 2021. e-Pub 2021. PMID: 33747356.
54. Pemmaraju N, Wilson NR, Clementi Doan T, Qiao W, Peterson SK, Zoeller V, Schorr A, Verstovsek S. Myeloproliferative neoplasm questionnaire: assessing patient disease knowledge in the modern digital information era. Leuk Lymphoma 62(9):2253-2260, 2021. e-Pub 2021. PMID: 33749512.
55. Yacoub A, Lyons R, Verstovsek S, Shao R, Chu DT, Agrawal A, Sivaraman S, Colucci P, Paranagama D, Mascarenhas J. Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Essential Thrombocythemia Enrolled in the MOST Study. Clin Lymphoma Myeloma Leuk 21(7):461-469, 2021. e-Pub 2021. PMID: 33839074.
56. Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, Welch MA, Dabaja BS, Daver N, Garcia-Manero G, Wierda W, Pemmaraju N, Montalban Bravo G, Thompson P, Verstovsek S, Konopleva M, Kantarjian H, Jabbour E. Treating Leukemia in the Time of COVID-19. Acta Haematol 144(2):132-144, 2021. e-Pub 2020. PMID: 32392559.
57. Masarova L, Bose P, Pemmaraju N, Daver N, Zhou L, Pierce S, Kantarjian H, Estrov Z, Verstovsek S. Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. Clin Lymphoma Myeloma Leuk 21(5):318-327, 2021. e-Pub 2021. PMID: 33551345.
58. Shahin OA, Chifotides HT, Bose P, Masarova L, Verstovsek S. Accelerated Phase of Myeloproliferative Neoplasms. Acta Haematol 144(5):484-489. [*the 2 authors share first authorship], 2021. e-Pub 2021. PMID: 33882481.
59. Tremblay D, Mesa R, Scott B, Buckley S, Roman-Torres K, Verstovsek S, Mascarenhas J. Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden. Blood Adv 4(23):5929-5935, 2020. PMID: 33275766.
60. Bose P, Masarova L, Verstovsek S. Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms. Cancers (Basel) 12(10):2891, 2020. e-Pub 2020. PMID: 33050168.
61. Chifotides HT, Masarova L, Alfayez M, Daver N, Alvarado Y, Jabbour E, Konopleva M, Kantarjian HM, Patel KP, DiNardo CD, Verstovsek S. Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Adv 4(21):5336-5342, 2020. PMID: 33112940.
62. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
63. Oh ST, Talpaz M, Gerds AT, Gupta V, Verstovsek S, Mesa R, Miller CB, Rivera CE, Fleischman AG, Goel S, Heaney ML, O'Connell C, Arcasoy MO, Zhang Y, Kawashima J, Ganz T, Kowalski M, Brachmann CB. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv 4(18):4282-4291, 2020. PMID: 32915978.
64. Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia 34(9):2489-2492, 2020. e-Pub 2020. PMID: 32099037.
65. Chifotides HT, Bose P, Verstovsek S. Givinostat: an emerging treatment for polycythemia vera. Expert Opinion Investig Drugs 29(6):525-536, 2020. e-Pub 2020. PMID: 32693648.
66. Masarova L, Bose P, Pemmaraju N, Daver NG, Zhou L, Pierce S, Sasaki K, Kantarjian HM, Estrov Z, Verstovsek S. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer 126(19):4322-4331, 2020. e-Pub 2020. PMID: 32697338.
67. Bose P, Verstovsek S. JAK inhibition for the treatment of myelofibrosis: Limitations and future perspectives. HemaSphere 4(4):e424, 2020. e-Pub 2020.
68. Ohanian M, Kantarjian HM, Shoukier M, Dellasala S, Musaelyan A, Nogueras Gonzalez GM, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Tamamyan G, Champlin R, Pierce S, Ferrajoli A, Kadia T, Cortes JE. The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. Am J Hematol, 2020. e-Pub 2020. PMID: 32557828.
69. Mughal TI, Pemmaraju N, Psaila B, Radich J, Bose P, Lion T, Kiladjian JJ, Rampal RK, Jain T, Verstovsek S, Yacoub A, Cortes JE, Mesa R, Saglio G, Van Etten RA. Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. Hematol Oncol 38(5):654-664, 2020. e-Pub 2020. PMID: 32592408.
70. Verstovsek S, Yu J, Kish JK, Paranagama D, Kaufman J, Myerscough C, Grunwald MR, Colucci P, Mesa R. Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States. Ann Hematol 99(11):2555-2564, 2020. e-Pub 2020. PMID: 32382773.
71. Gowin K, Ballen K, Ahn KW, Hu ZH, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, Gupta V, Hobbs G, Jain T, Kandarpa M, Komrokji R, Kuykendall AT, Luber K, Masarova L, Michaelis LC, Patches S, Pariser AC, Rampal RK, Stein B, Talpaz M, Verstovsek S, Wadleigh M, Agrawal V, Aljurf M, Angel Diaz M, Avalos BR, Bacher U, Bashey A, Beitinjaneh AM, Cerny J, Chhabra S, Copelan E, Cutler CS, DeFilipp Z, Gadalla SM, Ganguly S, Grunwald MR, Hashmi SK, Kharfan-Dabaja MA, Kindwall-Keller T, Kröger N, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Nathan S, Nishihori T, Olsson RF, Pawarode A, Rowe JM, Savani BN, Savoie ML, Seo S, Solh M, Tamari R, Verdonck LF, Yared JA, Alyea E, Popat U, Sobecks R, Scott BL, Nakamura R, Mesa R, Saber W. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv 4(9):1965-1973, 2020. PMID: 32384540.
72. Popat U, Mehta RS, Bassett R, Kongtim P, Chen J, Alousi AM, Anderlini P, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Pa RL, Nieto Y, Olson A, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson BS, Champlin RE. Optimizing the Conditioning Regimen for HCT in Myelofibrosis: Long-term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant 26(8):1439-1445, 2020. e-Pub 2020. PMID: 32438043.
73. Bose P, Verstovsek S. Management of myelofibrosis after ruxolitinib failure. Leuk Lymphoma 61(8):1797-1809, 2020. e-Pub 2020. PMID: 32297800.
74. Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Clinical value of event-free survival in acute myeloid leukemia. Blood Adv 4(8):1690-1699, 2020. e-Pub 2020. PMID: 32330243.
75. Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Jourdan E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Shen J, Berry T, Brownstein C, Mesa RA. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Am J Hematol 95(6):594-603, 2020. e-Pub 2020. PMID: 32129512.
76. Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol 95(2):144-150, 2020. e-Pub 2019. PMID: 31682008.
77. Saenz D, Fiskus W, Mill CP, Perera D, Manshouri T, Lara BH, Karkhanis V, Sharma S, Horrigan SK, Bose P, Kadia TM, Masarova L, DiNardo CD, Borthakur G, Khoury J, Takahashi K, Bhaskara S, Lin CY, Green MR, Coarfa C, Crews CM, Verstovsek S, Bhalla KN.. Mechanistic basis and efficacy of targeting β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors. Blood 135(15):1255-1269, 2020. PMID: 32068780.
78. Lopez-Mattei J, Verstovsek S, Fellman B, Iliescu C, Bhatti K, Hassan SA, Kim P, Gray BA, Palaskas NL, Grosu HB, Mamas MA, Faiz SA. Prevalence of pulmonary hypertension in myelofibrosis. Ann Hematol 99(4):781-789, 2020. e-Pub 2020. PMID: 32076825.
79. Fang H, Tang G, Loghavi S, Greipp P, Wang W, Verstovsek S, Medeiros LJ, Reichard K, Miranda RN, Wang SA. Systematic Use of Fluorescence in situ Hybridization (FISH) and Clinicopathological Features in the Screening of PDGFRB Rearrangements of Patients with Myeloid/Lymphoid Neoplasms. Histopathology 76(7):1042-1054, 2020. e-Pub 2020. PMID: 32083752.
80. Marcellino BK, Verstovsek S, Mascarenhas J. The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication. Clin Lymphoma Myeloma Leuk 20(7):415-421, 2020. e-Pub 2020. PMID: 32199764.
81. Fuentes-Mattei E, Bayraktar R, Manshouri T, Silva AM, Ivan C, Gulei D, Fabris L, Soares do Amaral N, Mur P, Perez C, Torres-Claudio E, Dragomir MP, Badillo-Perez A, Knutsen E, Narayanan P, Golfman L, Shimizu M, Zhang X, Zhao W, Ho WT, Estecio MR, Bartholomeusz G, Tomuleasa C, Berindan-Neagoe I, Zweidler-McKay PA, Estrov Z, Zhao ZJ, Verstovsek S, Calin GA, Redis RS. miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2. JCI Insight 5(1):e12178, 2020. PMID: 31941838.
82. Kiladjian JJ, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, Mesa R, Miller CB, Passamonti F, Durrant S, Griesshammer M, Kirito K, Besses C, Moiraghi B, Rumi E, Rosti V, Blau IW, Francillard N, Dong T, Wroclawska M, Vannucchi AM, Verstovsek S. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol 7(3):e226-e237, 2020. e-Pub 2020. PMID: 31982039.
83. Maiti A, Cortes JE, Patel KP, Masarova L, Borthakur G, Ravandi F, Verstovsek S, Ferrajoli A, Estrov Z, Garcia-Manero G, Kadia TM, Nogueras-González GM, Skinner J, Poku R, DellaSala S, Luthra R, Jabbour EJ, O'Brien S, Kantarjian HM. Long-term results of frontline dasatinib in chronic myeloid leukemia. Cancer 126(7):1502-1511, 2020. e-Pub 2020. PMID: 31999839.
84. Masarova L, Cortes JE, Patel KP, O'Brien S, Nogueras-Gonzalez GM, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia TM, Ravandi-Kashani F, Borthakur G, DellaSala S, Estrov Z, Jabbour EJ, Kantarjian HM. Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer 126(7):1448-1459, 2020. e-Pub 2020. PMID: 31999850.
85. Ye MT, Wang Y, Wang SA, Pemmaraju N, Daver N, Verstovsek S, Zhang Y, Zuo Z, Medeiros LJ, You MJ.. Concurrent JAK2 V617F and MPL W515L in myelodysplastic/ myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leuk Lymphoma 61(4):963-966, 2019. PMID: 31750750.
86. Santos FPS, Getta B, Masarova L, Famulare C, Schulman J, Datoguia TS, Puga RD, Alves Paiva RM, Arcila ME, Hamerschlak N, Kantarjian HM, Levine RL, Campregher PV, Rampal RK, Verstovsek S. Prognostic impact of RAS-pathway mutations in patients with myelofibrosis. Leukemia 34(3):799-810, 2019. PMID: 31628430.
87. Abou Dalle I, Kantarjian H, Burger J, Estrov Z, Ohanian M, Verstovsek S, Ravandi F, Borthakur G, Garcia-Manero G, Jabbour E, Cortes J. Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Medicine 8(15):6559-6565, 2019. PMID: 31502383.
88. Manshouri T, Verstovsek S, Harris DM, Veletic I, Zhang X, Post SM, Bueso-Ramos CE, Estrov Z. Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes. PloS One 14(9):e0222912, 2019. e-Pub 2019. PMID: 31569199.
89. Gotlib J, Baird JH, George TI, Langford C, Reyes I, Abuel J, Perkins C, Schroeder K, Bose P, Verstovsek S. A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. Blood Adv 3(15):2264-2271, 2019. PMID: 31350306.
90. Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma 60(7):1767-1774, 2019. e-Pub 2019. PMID: 30632841.
91. Strati P, Abdelrahim M, Selamet U, Page VD, Pierce SA, Verstovsek S, Abudayyeh A. Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis. Ann Hematol 98(7):1611-1616, 2019. e-Pub 2019. PMID: 31093708.
92. Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN. Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia 33(6):1373-1386, 2019. e-Pub 2018. PMID: 30575820.
93. Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, Kantarjian HM, Andreeff M, Verstovsek S. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer 125(11):1855-1866, 2019. e-Pub 2019. PMID: 30811597.
94. Bose P, Verstovsek S. MF Management. HemaSphere 3(S2):149-152, 2019.
95. Veletic I, Manshouri T, Multani AS, Yin CC, Chen L, Verstovsek S, Estrov Z. Myelofibrosis osteoclasts are clonal and functionally impaired. Blood 133(21):2320-2324, 2019. e-Pub 2019. PMID: 30745304.
96. Pemmaraju N, Kantarjian H, Nastoupil L, Dupuis M, Zhou L, Pierce S, Patel KP, Masarova L, Cortes J, Verstovsek S. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood 133(21):2348-2351, 2019. e-Pub 2019. PMID: 30796023.
97. Boddu P, Jain P, Borthakur G, Verstovsek S, Garcia-Manero G, Daver N, Kadia T, Ravandi F, Jabbour E, Cortes J, Kantarjian H. Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. Leuk Lymphoma 60(13):3172-3180, 2019. e-Pub 2019. PMID: 31125272.
98. Veletic I, Manshouri T, Newberry KJ, Garnett J, Verstovsek S, Estrov Z. Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis. Br J Haematol 185(2):382-386, 2019. e-Pub 2018. PMID: 30074241.
99. Hu Z, Ramos CEB, Medeiros LJ, Zhao C, Yin CC, Li S, Hu S, Wang W, Thakral B, Xu J, Verstovsek S, Lin P. Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic leukemia from primary myelofibrosis with monocytosis. Human Pathol 85:290-298, 2019. e-Pub 2018. PMID: 30447300.
100. Jain P, Kantarjian H, Boddu PC, Nogueras-González GM, Verstovsek S, Garcia-Manero G, Borthakur G, Sasaki K, Kadia TM, Sam P, Ahaneku H, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Cortes JE. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv 3(6):851-861, 2019. PMID: 30885996.
101. Strati P, Glass WF, Abdelrahim M, Selamet U, Tchakarov A, Workeneh BT, Verstovsek S, Abudayyeh A. Renal complications of primary myelofibrosis. Leuk Lymphoma 60(2):1-4, 2019. e-Pub 2018. PMID: 29966471.
102. Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma 60(1):1-12, 2019. e-Pub 2018. PMID: 29741984.
103. Swaminathan M, Patel KP, Huynh-Lu J, Tang G, Zuo Z, Miranda R, Verstovsek S. Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript. Acta Haematol 141(1):23-27, 2019. e-Pub 2018. PMID: 30463063.
104. Shah MV, Patel KP, Luthra R, Kanagal-Shamanna R, Mehrotra M, Bachegowda LS, Champlin RE, Verstovsek S, Popat UR. Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation. Br J Haematol 183(5):831-835, 2018. e-Pub 2017. PMID: 29265180.
105. Boddu P, Chihara D, Masarova L, Pemmaraju N, Patel KP, Verstovsek S. The co-occurrence of driver mutations in chronic myeloproliferative neoplasms. Ann Hematol 97(11):2071-2080, 2018. e-Pub 2018. PMID: 29951914.
106. Hu Z, Boddu PC, Loghavi S, Miranda RN, Goswami M, Medeiros LJ, Tam W, Orazi A, Verstovsek S, Wang SA. A Multimodality Work-up of Patients with Hypereosinophilia. Am J Hematol 93(11):1337-1346, 2018. e-Pub 2018. PMID: 30105844.
107. Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S. Mutational landscape of myelodysplastic/myeloproliferative neoplasm - unclassifiable (MDS/MPN-U). Blood 132(19):2100-2103, 2018. e-Pub 2018. PMID: 30242087.
108. Verstovsek S, Yeleswaram S, Hou K, Chen X, Erickson-Viitanen S. Sustained-Release Ruxolitinib: Findings From a Phase 1 Study in Healthy Subjects and a Phase 2 Study in Patients With Myelofibrosis. Hematol Oncol 36(4):701-708, 2018. e-Pub 2018. PMID: 30105794.
109. Abaza Y, Hidalgo-Lopez JE, Verstovsek S, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Alvarado Y, Burger J, Schneider H, Soltysiak KA, Wei Y, Kantarjian HM, Bueso-Ramos CE, Garcia-Manero G. Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res 73:78-85, 2018. PMID: 30245189.
110. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis. Blood 132(16):1664-1674, 2018. PMID: 30185431.
111. Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol 5(9):e411-e421, 2018. e-Pub 2018. PMID: 30115541.
112. Couban S, Benevolo G, Donnellan W, Cultrera J, Koschmieder S, Verstovsek S, Hooper G, Hertig C, Tandon M, Dimier N, Malhi V, Passamonti F. A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis. J Hematol Oncol 11(1):122, 2018. e-Pub 2018. PMID: 30249277.
113. Verstovsek S, Subbiah V, Masarova L, Yin CC, Tang G, Manshouri T, Asatiani E, Daver NG. Treatment of the Myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 Inhibitor. Ann Oncol 29(8):1880-1882, 2018. e-Pub 2018. PMID: 29767670.
114. Jennings SV, Slee VM, Zack RM, Verstovsek S, George TI, Shi H, Lee P, Castells MC. Patient Perceptions in Mast Cell Disorders. Immunol Allergy Clin North Am 38(3):505-525, 2018. PMID: 30007467.
115. Khan M, Muzzafar T, Kantarjian H, Badar I, Short N, Wang X, Chamoun K, Jain P, DiNardo C, Pemmaraju N, Bose P, Borthakur G, Cortes J, Verstovsek S, Garcia-Manero G, Estrov Z. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol 97(7):1183-1191, 2018. e-Pub 2018. PMID: 29557496.
116. Harrison CN, Griesshammer M, Miller C, Masszi T, Passamonti F, Zachee P, Durrant S, Pane F, Guglielmelli P, Verstovsek S, Jones MM, Hunter DS, Sun W, Li J, Khan M, Habr D, Kiladjian JJ. Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide. Br J Haematol 182(2):279-284, 2018. e-Pub 2017. PMID: 29984424.
117. Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol 4(5):652-659, 2018. e-Pub 2018. PMID: 29522138.
118. Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32(5):1057-1069, 2018. e-Pub 2018. PMID: 29515238.
119. Kiladjian JJ, Guglielmelli P, Griesshammer M, Saydam G, Masszi T, Durrant S, Passamonti F, Jones M, Zhen H, Li J, Gadbaw B, Perez Ronco J, Khan M, Verstovsek S. Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. Ann Hematol 97(4):617-627, 2018. e-Pub 2018. PMID: 29396713.
120. Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-center, open-label, dose-escalation, phase 1/1b trial. Lancet Haematol 5(4):e136-e146, 2018. e-Pub 2018. PMID: 29550383.
121. Shah MY, Ferracin M, Pileczki V, Chen B, Redis R, Fabris L, Zhang X, Ivan C, Shimizu M, Rodriguez-Aguayo C, Dragomir M, Van Roosbroeck K, Almeida MI, Ciccone M, Nedelcu D, Cortez MA, Manshouri T, Calin S, Muftuoglu M, Banerjee PP, Badiwi MH, Parker-Thornburg J, Multani A, Welsh JW, Estecio MR, Ling H, Tomuleasa C, Dima D, Yang H, Alvarez H, You MJ, Radovich M, Shpall E, Fabbri M, Rezvani K, Girnita L, Berindan-Neagoe I, Maitra A, Verstovsek S, Fodde R, Bueso-Ramos C, Gagea M, Manero GG, Calin GA. Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res 28(4):432-447, 2018. e-Pub 2018. PMID: 29567676.
122. Masarova L, Alhuraiji A, Bose P, Daver N, Pemmaraju N, Cortes J, Pierce S, Kantarjian H, Verstovsek S. Significance of thrombocytopenia in patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Eur J Haematol 100(3):257-263, 2018. e-Pub 2018. PMID: 29226426.
123. Hidalgo López JE, Carballo-Zarate A, Verstovsek S, Wang SA, Hu S, Li S, Xu J, Zuo W, Tang Z, Yin CC, Medeiros LJ, Bueso-Ramos CE, Tang G. Bone marrow findings in blast phase of polycythemia vera. Ann Hematol 97(3):425-434, 2018. e-Pub 2017. PMID: 29285580.
124. Kvasnicka HM, Thiele J, Bueso-Ramos CE, Sun W, Cortes J, Kantarjian HM, Verstovsek S. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. J Hematol Oncol 11(1):42, 2018. e-Pub 2018. PMID: 29544547.
125. Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): A randomized, open-label, phase 3 trial. Lancet Haematol 5(2):e73-e81, 2018. e-Pub 2017. PMID: 29275119.
126. Alhuraiji A, Naqvi K, Huh YO, Ho C, Verstovsek S, Bose P. Acute lymphoblastic leukemia secondary to myeloproliferative neoplasms or after lenalidomide exposure. Clin Case Rep 6(1):155-161, 2018. e-Pub 2017. PMID: 29375856.
127. Maiti A, Short NJ, Verstovsek S, Powers CA, Fullmer CA, Reyes SR, Bueso-Ramos CE. Quality and cost comparison of powered versus manual bone marrow biopsy devices in patients with myelofibrosis. Leuk Lymphoma 58(10):1-3, 2017. e-Pub 2017. PMID: 28264600.
128. Tang G, Hidalgo Lopez JE, Wang SA, Hu S, Ma J, Pierce S, Zuo W, Carballo-Zarate AA, Yin CC, Tang Z, Li S, Medeiros LJ, Verstovsek S, Bueso-Ramos CE. Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. Haematologica 102(9):1511-1518, 2017. e-Pub 2017. PMID: 28473622.
129. Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, Bose P, Daver N, Cortes J, Kantarjian H, Verstovsek S. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood 130(9):1125-1131, 2017. e-Pub 2017. PMID: 28674026.
130. Vannucchi AM, Verstovsek S, Guglielmelli P, Griesshammer M, Burn TC, Naim A, Paranagama D, Marker M, Gadbaw B, Kiladjian JJ. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Ann Hematol 96(7):1113-1120, 2017. e-Pub 2017. PMID: 28456851.
131. Hidalgo-López JE, Kanagal-Shamanna R, Medeiros LJ, Estrov Z, Yin CC, Verstovsek S, Konoplev S, Jorgensen JL, Mohammad MM, Miranda RN, Zhao C, Lee J, Zuo Z, Bueso-Ramos CE. Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation. J Natl Compr Canc Netw 15(6):790-796, 2017. PMID: 28596259.
132. Verstovsek S, Harrison CN, Kiladjian JJ, Miller C, Naim AB, Paranagama DC, Habr D, Vannucchi AM. Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. Leuk Res 56:52-59, 2017. e-Pub 2017. PMID: 28193568.
133. Strati P, Bose P, Lyle L, Gaw K, Zhou L, Pierce SA, Huynh-Lu J, Hirsch-Ginsberg CF, Bueso-Mendoza DE, Bueso-Ramos CE, Verstovsek S. Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions. Ann Hematol 96(5):733-738, 2017. e-Pub 2017. PMID: 28247057.
134. Wang SA, Hasserjian RP, Tam W, Tsai AG, Geyer JT, George TI, Foucar K, Rogers HJ, Hsi ED, Rea BA, Bagg A, Bueso-Ramos C C, Arber DA, Verstovsek S, Orazi A. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified from reactive idiopathic hypereosinophilic syndrome. Haematologica 102(8):1352-1360, 2017. e-Pub 2017. PMID: 28495918.
135. Abaza Y, Yin CC, Bueso-Ramos CE, Wang SA, Verstovsek S. Primary autoimmune myelofibrosis: a case report and review of the literature. Int J Hematol 105(4):536-539, 2017. e-Pub 2016. PMID: 27830539.
136. Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer 123(16):3050-3060, 2017. e-Pub 2017. PMID: 28387922.
137. Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, Estrov Z, Kantarjian H, Verstovsek S. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol 4(4):e165-e175, 2017. e-Pub 2017. PMID: 28291640.
138. Verstovsek S, Savona MR, Mesa RA, Dong H, Maltzman JD, Sharma S, Silverman J, Oh ST, Gotlib J. A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis. Br J Haematol 176(6):939-949, 2017. e-Pub 2017. PMID: 28220932.
139. Jain P, Wang SA, Yin CC, Abaza Y, Verstovsek S, Estrov Z. A case of lymphocytic variant hypereosinophilic syndrome with sub-diagnostic systemic mastocytosis. Blood Res 52(1):71-73, 2017. e-Pub 2017. PMID: 28401108.
140. Koller PB, Kantarjian HM, Nogueras-Gonzalez GM, Jabbour E, Verstovsek S, Borthakur G, Estrov Z, Wierda WG, Garcia-Manero G, Ferrajoli A, Ravandi F, O'Brien SM, Cortes JE. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer 123(4):609-616, 2017. e-Pub 2016. PMID: 27763690.
141. Jabbour E, Faderl S, Sasaki K, Kadia T, Daver N, Pemmaraju N, Patel K, Khoury JD, Bueso-Ramos C, Bohannan Z, Ravandi F, Borthakur G, Verstovsek S, Miller D, Maduike R, Hosing C, Kantarjian HM, Garcia-Manero G. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer 123(4):629-637, 2017. e-Pub 2016. PMID: 27741352.
142. Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia 31(2):318-324, 2017. e-Pub 2016. PMID: 27795561.
143. Mascarenhas JO, Talpaz M, Gupta V, Foltz LM, Savona MR, Paquette R, Turner AR, Coughlin P, Winton E, Burn TC, O'Neill P, Clark J, Hunter D, Assad A, Hoffman R, Verstovsek S. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica 102(2):327-335, 2017. e-Pub 2016. PMID: 27789678.
144. Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H, COMFORT-I investigators. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 10(1):55, 2017. e-Pub 2017. PMID: 28228106.
145. Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol 4(2):e67-e74, 2017. e-Pub 2017. PMID: 28089238.
146. Lortholary O, Chandesris MO, Bulai Livideanu C, Paul C, Guillet G, Jassem E, Niedoszytko M, Barete S, Verstovsek S, Grattan C, Damaj G, Canioni D, Fraitag S, Lhermitte L, Georgin Lavialle S, Frenzel L, Afrin LB, Hanssens K, Agopian J, Gaillard R, Kinet JP, Auclair C, Mansfield C, Moussy A, Dubreuil P, Hermine O. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet 389(10069):612-620, 2017. e-Pub 2017. PMID: 28069279.
147. Mesa R, Vannucchi AM, Yacoub A, Zachee P, Garg M, Lyons R, Koschmieder S, Rinaldi C, Byrne J, Hasan Y, Passamonti F, Verstovsek S, Hunter D, Jones MM, Zhen H, Habr D, Martino B. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). Br J Haematol 176(1):76-85, 2017. e-Pub 2016. PMID: 27858987.
148. Gupta V, Harrison C, Hexner EO, Al-Ali HK, Foltz L, Montgomery M, Sun W, Gopalakrishna P, Kantarjian H, Verstovsek S. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies. Haematologica 101(12):e482-e484, 2016. e-Pub 2016. PMID: 27587385.
149. Verstovsek S, Odenike O, Singer JW, Granston T, Al-Fayoumi S, Deeg HJ. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J Hematol Oncol 9(1):137, 2016. e-Pub 2016. PMID: 27931243.
150. Chihara D, Masarova L, Newberry KJ, Maeng H, Ravandi F, Garcia-Manero G, Ferrajoli A, Cortes J, Kantarjian H, Verstovsek S. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leuk Res 48:1-5, 2016. e-Pub 2016. PMID: 27416326.
151. Mesa R, Verstovsek S, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Zhen H, Jones MM, Parasuraman S, Li J, Côté I, Habr D, Vannucchi AM. Changes in Quality of Life and Disease-Related Symptoms in Patients With Polycythemia Vera Receiving Ruxolitinib or Standard Therapy. Eur J Haematol 97(2):192-200, 2016. e-Pub 2016. PMID: 26608702.
152. Jain P, Verstovsek S, Wang W, Loghavi S, Torres HA, Estrov Z, Patel KP, Pemmaraju N. DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. Leuk Lymphoma 57(8):1-5, 2016. e-Pub 2015. PMID: 26700872.
153. Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, Nakamura R, Kluin-Nelemans HC, Verstovsek S, Gajewski J, Perales MA, George T, Shore T, Sperr W, Saber W, Kota V, Yavuz AS, Pullarkat V, Rogosheske J, Hogan W, Van Besien K, Hagglund H, Damaj G, Arock M, Horny HP, Metcalfe DD, Deeg HJ, Devine S, Weisdorf D, Akin C, Valent P. Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. Biol Blood Marrow Transplant 22(8):1348-1356, 2016. e-Pub 2016. PMID: 27131865.
154. Wang SA, Tam W, Tsai AG, Arber DA, Hasserjian RP, Geyer JT, George TI, Czuchlewski DR, Foucar K, Rogers HJ, Hsi ED, Bryan Rea B, Bagg A, Dal Cin P, Zhao C, Kelley TW, Verstovsek S, Bueso-Ramos C, Orazi A. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Mod Pathol 29(8):854-64, 2016. e-Pub 2016. PMID: 27174585.
155. Masarova L, Wang W, Newberry KJ, Kantarjian H, Verstovsek S. Complete hematologic, histomorphologic, cytogenetic, and molecular remission in a patient with JAK2- and IDH2-positive myelofibrosis. Blood 128(6):877-80, 2016. e-Pub 2016. PMID: 27325105.
156. Verstovsek S, Manshouri T, Pilling D, Bueso-Ramos CE, Newberry KJ, Prijic S, Knez L, Bozinovic K, Harris DM, Spaeth EL, Post SM, Multani AS, Rampal RK, Ahn J, Levine RL, Creighton CJ, Kantarjian HM, Estrov Z. Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med 213(9):1723-40, 2016. PMID: 27481130.
157. Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, Besses C, Hino M, Moiraghi B, Miller CB, Cazzola M, Rosti V, Blau I, Mesa R, Jones MM, Zhen H, Li J, Francillard N, Habr D, Kiladjian JJ. Ruxolitinib versus best available therapy in patients with Polycythemia Vera: 80 Week follow up from the RESPONSE trial. Haematologica 101(7):821-9, 2016. e-Pub 2016. PMID: 27102499.
158. Verstovsek S, Atallah E, Mascarenhas J, Sun H, Montgomery M, Gupta V, Mesa R, Gotlib J. Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis. Leukemia 30(6):1413-5, 2016. e-Pub 2015. PMID: 26526986.
159. Todisco G, Manshouri T, Verstovsek S, Masarova L, Pierce SA, Keating MJ, Estrov Z. Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics. Leuk Lymphoma 57(5):1-6, 2016. e-Pub 2015. PMID: 26402369.
160. Rozovski U, Harris DM, Li P, Liu Z, Wu JY, Grgurevic S, Faderl S, Ferrajoli A, Wierda WG, Martinez M, Verstovsek S, Keating MJ, Estrov Z. At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells. J Immunol 196(10):4400-9, 2016. e-Pub 2016. PMID: 27076684.
161. Jain P, Kantarjian H, Sasaki K, Jabbour E, Dasarathula J, Nogueras Gonzalez G, Verstovsek S, Borthakur G, Wierda W, Kadia T, Dellasala S, Pierce S, Ravandi F, O'Brien S, Cortes J. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. Br J Haematol 173(1):114-26, 2016. e-Pub 2016. PMID: 26846160.
162. Pemmaraju N, Kantarjian H, Ravandi F, Nogueras-Gonzalez GM, Huang X, O'Brien S, Wierda W, Garcia-Manero G, Thomas D, Pierce S, Verstovsek S, Borthakur G, Cortes J. Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clin Lymphoma Myeloma Leuk 16(4):213-222.e2, 2016. e-Pub 2016. PMID: 26838606.
163. Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis With Prior exposure to JAK1/2 Inhibitors. Biol Blood Marrow Transplant 22(3):432-40, 2016. e-Pub 2015. PMID: 26493563.
164. Loghavi S, Bueso-Ramos CE, Kanagal-Shamanna R, Ok CY, Salim AA, Routbort MJ, Mehrotra M, Verstovsek S, Medeiros LJ, Luthra R, Patel KP. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features. Am J Clin Pathol 145(3):418-27, 2016. PMID: 27124925.
165. Daver N, Kantarjian H, Ravandi F, Estey E, Wang X, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Verstovsek S, Kadia T, DiNardo C, Pierce S, Huang X, Pemmaraju N, Diaz-Pines-Mateo M, Cortes J, Borthakur G. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia 30(2):268-73, 2016. e-Pub 2015. PMID: 26365212.
166. Masarova L, Cherry M, Newberry KJ, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek S. Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience. Leuk Lymphoma 57(1):1-10, 2016. e-Pub 2015. PMID: 25904378.
167. Singer JW, Al-Fayoumi S, Ma H, Komrokji RS, Mesa R, Verstovsek S. Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor. J Exp Pharmacol 8:11-19, 2016. e-Pub 2016. PMID: 27574472.
168. Chen Z, Wang W, Verstovsek S, Cortes JE, Medeiros LJ, Hu S. Chronic myelogenous leukemia in patients with MPL or JAK2 mutation-positive myeloproliferative neoplasm. Int J Lab Hematol 37(6):e150-2, 2015. e-Pub 2015. PMID: 26086872.
169. Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 121(23):4158-64, 2015. e-Pub 2015. PMID: 26308885.
170. Mehrotra M, Luthra R, Singh RR, Barkoh BA, Galbincea J, Mehta P, Goswami RS, Jabbar KJ, Loghavi S, Medeiros LJ, Verstovsek S, Patel KP. Clinical Validation of a Multipurpose Assay for Detection and Genotyping of CALR Mutations in Myeloproliferative Neoplasms. Am J Clin Pathol 144(5):746-55, 2015. PMID: 26486739.
171. Jain P, Verstovsek S, Loghavi S, Jorgensen JL, Patel KP, Estrov Z, Fayad L, Pemmaraju N. Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome. Am J Hematol 90(11):1091-2, 2015. e-Pub 2015. PMID: 25808231.
172. Livun A, Newberry KJ, Manshouri T, Kusec R, Verstovsek S. Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3. Anticancer Res 35(10):5219-23, 2015. PMID: 26408680.
173. Badar T, Kantarjian HM, Ravandi F, Jabbour E, Borthakur G, Cortes JE, Pemmaraju N, Pierce SR, Newberry KJ, Daver N, Verstovsek S. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res 39(9):950-6, 2015. e-Pub 2015. PMID: 26183878.
174. Sanford D, DiNardo CD, Tang G, Cortes JE, Verstovsek S, Jabbour E, Ravandi F, Kantarjian H, Garcia-Manero G. Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clin Lymphoma Myeloma Leuk 15(9):556-62, 2015. e-Pub 2015. PMID: 26141213.
175. Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood 126(13):1551-4, 2015. e-Pub 2015. PMID: 26228487.
176. Masarova L, Newberry KJ, Pierce SA, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek S. Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome. Leuk Res 39(8):822-7, 2015. e-Pub 2015. PMID: 26012362.
177. Daver N, Cortes J, Newberry K, Jabbour E, Zhou L, Wang X, Pierce S, Kadia T, Sasaki K, Borthakur G, Ravandi F, Pemmaraju N, Kantarjian H, Verstovsek S. Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis. Haematologica 100(8):1058-63, 2015. e-Pub 2015. PMID: 26088933.
178. Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J, Singh R, Mehrotra M, Routbort MJ, Luthra M, Manshouri T, Santos FP, Kantarjian H, Verstovsek S. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood 126(6):790-7, 2015. e-Pub 2015. PMID: 26124496.
179. Rajasekaran A, Ngo TT, Abdelrahim M, Glass W, Podoll A, Verstovsek S, Abudayyeh A. Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib. BMC Nephrol 16:121, 2015. e-Pub 2015. PMID: 26232031.
180. Sasaki K, Gotlib JR, Mesa RA, Newberry KJ, Ravandi F, Cortes JE, Kelly P, Kutok JL, Kantarjian HM, Verstovsek S. Phase II Evaluation of IPI-926, an Oral Hedgehog Inhibitor, in Patients with Myelofibrosis. Leuk Lymphoma 56(7):1-20, 2015. e-Pub 2015. PMID: 25641433.
181. Badar T, Cortes JE, Ravandi F, O'Brien S, Verstovsek S, Garcia-Manero G, Kantarjian H, Borthakur G. Phase I Study of S-Trans, Trans-Farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients With Refractory Hematologic Malignancies. Clin Lymphoma Myeloma Leuk 15(7):433-438.e2, 2015. e-Pub 2015. PMID: 25795639.
182. Loghavi S, Pemmaraju N, Kanagal-Shamanna R, Mehrotra M, Medeiros LJ, Luthra R, Lin P, Huh Y, Kantarjian HM, Cortes JE, Verstovsek S, Patel KP. Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood 125(21):3360-3, 2015. PMID: 25999449.
183. Pieri L, Pancrazzi A, Pacilli A, Rabuzzi C, Rotunno G, Fanelli T, Guglielmelli P, Fjerza R, Paoli C, Verstovsek S, Vannucchi AM. JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib. Blood 125(21):3352-3, 2015. PMID: 25999444.
184. Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M, Levine R, Komrokji R, Klisovic R, Gundabolu K, Kropf P, Wetzler M, Oh ST, Ribeiro R, Paschal R, Mohan S, Podoltsev N, Prchal J, Talpaz M, Snyder D, Verstovsek S, Mesa RA. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. J Natl Compr Canc Netw 13(4):424-34, 2015. PMID: 25870379.
185. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H, COMFORT-I investigators. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica 100(4):479-88, 2015. e-Pub 2015. PMID: 25616577.
186. Mesa RA, Verstovsek S, Gupta V, Mascarenhas JO, Atallah E, Burn T, Sun W, Sandor V, Gotlib J. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. Clin Lymphoma Myeloma Leuk 15(4):214-221.e1, 2015. e-Pub 2014. PMID: 25682576.
187. Jain P, Kantarjian H, Alattar ML, Jabbour E, Sasaki K, Nogueras Gonzalez G, Dellasala S, Pierce S, Verstovsek S, Wierda W, Borthakur G, Ravandi F, O'Brien S, Cortes J. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. Lancet Haematol 2(3):e118-28, 2015. e-Pub 2015. PMID: 26687797.
188. Verstovsek S, Hoffman R, Mascarenhas J, Soria JC, Bahleda R, McCoon P, Tang W, Cortes J, Kantarjian H, Ribrag V. A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis. Leuk Res 39(2):157-63, 2015. e-Pub 2014. PMID: 25530567.
189. Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(5):426-35, 2015. PMID: 25629741.
190. Rampal RK, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D, Otto GA, Yelensky R, Hricik T, McKenney AS, Chiosis G, Chung YR, Pandey S, van den Brink MR, Armstrong SA, Dogan A, Intlekofer A, Manshouri T, Park CY, Verstovsek S, Rapaport F, Stephens PJ, Miller VA, Levine RL. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci USA 111(50):E5401-10, 2014. e-Pub 2014. PMID: 25516983.
191. Falchi L, Mehrotra M, Newberry KJ, Lyle LM, Lu G, Patel KP, Luthra R, Popat U, Verstovsek S. ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant. Leukemia 28(10):2090-2, 2014. e-Pub 2014. PMID: 24854988.
192. Daver N, Shastri A, Kadia T, Newberry K, Pemmaraju N, Jabbour E, Zhou L, Pierce S, Cortes J, Kantarjian H, Verstovsek S. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res 38(9):1126-9, 2014. e-Pub 2014. PMID: 25047979.
193. DiNardo CD, Daver N, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC, Pierce S, Jabbour E, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia 28(4):958-61, 2014. e-Pub 2014. PMID: 24492324.
194. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, Gattoni E, Pieri L, Guglielmelli P, Elena C, He S, Contel N, Mookerjee B, Sandor V, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 120(4):513-20, 2014. e-Pub 2013. PMID: 24258498.
195. Santos FP, Tam CS, Kantarjian H, Cortes J, Thomas D, Pollock R, Verstovsek S. Splenectomy in patients with Myeloproliferative Neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma 55(1):121-7, 2014. e-Pub 2013. PMID: 23573823.
196. Pemmaraju N, Chang E, Daver N, Patel K, Jorgensen J, Sabloff B, Verstovsek S, Borthakur G. Extramedullary acute myeloid leukemia: leukemic pleural effusion, case report and review of the literature. Front Oncol 4:130, 2014. e-Pub 2014. PMID: 24918086.
197. Sever M, Quintás-Cardama A, Pierce S, Zhou L, Kantarjian H, Verstovsek S. Significance of Cytogenetic Abnormalities in Patients with Polycythemia Vera. Leuk Lymphoma 54(12):2667-70, 2013. e-Pub 2013. PMID: 23488603.
198. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 98(12):1865-71, 2013. e-Pub 2013. PMID: 24038026.
199. Nazha A, Estrov Z, Cortes J, Bueso-Ramos CE, Kantarjian H, Verstovsek S. Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. Leuk Lymphoma 54(11):2537-9, 2013. e-Pub 2013. PMID: 23343175.
200. Daver N, Shastri A, Kadia T, Quintas-Cardama A, Jabbour E, Konopleva M, O'Brien S, Pierce S, Zhou L, Cortes J, Kantarjian H, Verstovsek S. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res 37(11):1440-4, 2013. e-Pub 2013. PMID: 23890523.
201. Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, List AF, Sebti S, Kantarjian HM, Ravandi F, Lancet JE. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leuk Res 37(11):1461-7, 2013. e-Pub 2013. PMID: 23993427.
202. Cherry M, Cardenas-Turanzas M, Pham H, Kantarjian H, Cortes J, Pierce S, Zhou L, Verstovsek S. Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome. Leuk Res 37(11):1472-6, 2013. e-Pub 2013. PMID: 23993426.
203. Takahashi K, Patel KP, Kantarjian H, Luthra R, Pierce S, Cortes J, Verstovsek S. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms. Blood 122(23):3784-6, 2013. e-Pub 2013. PMID: 24068492.
204. Mesa RA, Shields A, Hare T, Erickson-Viitanen S, Sun W, Sarlis NJ, Sandor V, Levy RS, Verstovsek S. Progressive burden of myelofibrosis in untreated patients: Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study. Leuk Res 37(8):911-6, 2013. e-Pub 2013. PMID: 23684482.
205. Quintás-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, Zhang SJ, Harris D, Estrov Z, Kantarjian H, Levine RL, Verstovsek S. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. Blood 122(6):893-901, 2013. e-Pub 2013. PMID: 23782935.
206. Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, Gotlib J, Dupriez B, Pardanani A, Harrison C, Hoffman R, Gisslinger H, Kröger N, Thiele J, Barbui T, Barosi G. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European LeukemiaNet (ELN) consensus report. Blood 122(8):1395-8, 2013. e-Pub 2013. PMID: 23838352.
207. Quintás-Cardama A, Kantarjian H, Pierce S, Cortes J, Verstovsek S. Prognostic Model to Identify Patients With Myelofibrosis at the Highest Risk of Transformation to Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 13(3):315-318.e2, 2013. e-Pub 2013. PMID: 23391717.
208. Takahashi K, Cortes J, Pierce S, Abruzzo L, Kantarjian H, Verstovsek S. Chromosome 5q deletion is extremely rare in patients with myelofibrosis. Leuk Res 37(5):552-5, 2013. e-Pub 2013. PMID: 23391517.
209. Fiskus W, Verstovsek S, Manshouri T, Smith JE, Peth K, Abhyankar S, McGuirk J, Bhalla KN. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells. Mol Cancer Ther 12(5):577-88, 2013. e-Pub 2013. PMID: 23445613.
210. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol 161(4):508-16, 2013. e-Pub 2013. PMID: 23480528.
211. Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Hare T, Erickson-Viitanen S, Sun W, Sandor V, Levy RS, Kantarjian HM, Verstovsek S. Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Oncol 31(10):1285-92, 2013. e-Pub 2013. PMID: 23423753.
212. Jain P, Verstovsek S, Orlowski RZ, Yap E, Amin HM. An Unusual Case of Aggressive Systemic Mastocytosis With Associated Refractory Plasma Cell Myeloma. Clin Lymphoma Myeloma Leuk 12(6):459-62, 2012. e-Pub 2012. PMID: 23009979.
213. Benjamini O, Jain P, Estrov Z, Kantarjian HM, Verstovsek S. Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly. Blood 120(13):2768-9, 2012. PMID: 23019204.
214. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E, Morra E, Caramazza D, Cazzola M, Passamonti F. Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 120(6):1202-9, 2012. e-Pub 2012. PMID: 22718840.
215. Zhang SJ, Rampal RK, Manshouri T, Patel J, Mensah N, Kayserian A, Hricik T, Heguy A, Hedvat C, Gönen M, Kantarjian H, Levine RL, Abdel-Wahab O, Verstovsek S. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms reveals recurrent SRSF2 mutations which are associated with adverse outcome. Blood 119(19):4480-5, 2012. e-Pub 2012. PMID: 22431577.
216. Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including post-myeloproliferative neoplasm acute myeloid leukemia. Blood 119(20):4614-8, 2012. e-Pub 2012. PMID: 22422826.
217. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799-807, 2012. PMID: 22375971.
218. Jabbour E, Thomas D, Kantarjian H, Zhou L, Pierce S, Cortes J, Verstovsek S. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood 118(4):899-902, 2011. e-Pub 2011. PMID: 21622644.
219. Manshouri T, Estrov Z, Quintás-Cardama A, Burger J, Zhang Y, Livun A, Knez L, Harris D, Creighton CJ, Kantarjian HM, Verstovsek S. Bone Marrow Stroma Secreted Cytokines Protect JAK2V617F-Mutated Cells From the Effects of a JAK2 Inhibitor. Cancer Res 71(11):3831-40, 2011. e-Pub 2011. PMID: 21512135.
220. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. N Engl J Med 363(12):1117-27, 2010. PMID: 20843246.
221. Verstovsek S, Lunin S, Kantarjian H, Manshouri T, Faderl S, Cortes J, Giles F, Albitar M. Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. Leuk Res 27:661-669, 2003. PMID: 12681367.
222. Khan M, Yin CC, Yates A, Newberry KJ, Verstovsek S. A Rare Case of Primary Myelofibrosis in a 14-Year-Old Patient with Congenital Asplenia. J Pediatr Hematol Oncol. e-Pub 2016. PMID: 27403772.
223. Jain P, Wang S, Patel KP, Sarwari N, Cortes J, Kantarjian H, Verstovsek S. Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome. Leuk Res 59:105-109. e-Pub 2017. PMID: 28599188.
224. Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek S. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res 59:110-116. e-Pub 2017. PMID: 28601551.
225. Miller CB, Komrokji RS, Mesa RA, Sun W, Montgomery M, Verstovsek S. Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I. Clin Lymphoma Myeloma Leuk 17(8):479-487. e-Pub 2017. PMID: 28606598.
226. Verstovsek S, Courby S, Griesshammer M, Mesa RA, Brachmann CB, Kawashima J, Maltzman JD, Shao L, Xin Y, Huang D, Bajel A. A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. Leuk Res 60:11-17. e-Pub 2017. PMID: 28622623.
227. Short NJ, Kantarjian HM, Ko H, Khoury JD, Ravandi F, Thomas DA, Garcia-Manero G, Khouri M, Cortes JE, Wierda WG, Verstovsek S, Estrov Z, Ferrajoli A, Thompson PA, Pierce S, O'Brien SM, Jabbour E. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol 92(6):E114-E117. e-Pub 2017. PMID: 28295472.
228. Strati P, Masarova L, Bose P, Daver N, Pemmaraju N, Verstovsek S. Haptoglobin is Frequently Low in Patients with Myelofibrosis: Clinical Relevance. Leuk Res 57:85-88. e-Pub 2017. PMID: 28324773.
229. Hu Z, Medeiros LJ, Wang W, Chen Z, Tang G, Hodjat P, Yang S, Fang L, Li Y, Verstovsek S, Hu S. 3q26.2/EVI1 rearrangement is associated with poor prognosis in classical Philadelphia chromosome-negative myeloproliferative neoplasms. Mod Pathol 30(7):940-951. e-Pub 2017. PMID: 28338652.
230. Saenz DT, Fiskus W, Qian Y, Manshouri T, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Mill CP, Sun B, Qiu P, Kadia TM, Pemmaraju N, DiNardo C, Kim MS, Nowak AJ, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. Leukemia 31(9):1951-1961. e-Pub 2017. PMID: 28042144.
231. Bose P, Verstovsek S. JAK2 inhibitors for Myeloproliferative Neoplasms: What Is Next?. Blood 130(2):115-125. e-Pub 2017. PMID: 28500170.

Invited Articles

1. Chifotides HT, Verstovsek S. EXABS-164-MPN-Novel Therapeutics in Development for Myelofibrosis. Clin Lymph Myeloma Leuk 22 (Suppl. 2)(S2):S72-S74, 2022. e-Pub 2022.
2. Verstovsek S. How early intervention impacts long-term survival in myelofibrosis. Clin Adv Hematol Oncol 20(5):291-294, 2022. e-Pub 2022. PMID: 35579587.
3. Mascarenhas J, Gerds A, Verstovsek S. Paradigm shift: combination BET and JAK inhibition in myelofibrosis. Leukemia 35(12):3361-3363, 2021. e-Pub 2021. PMID: 34480105.
4. Chifotides HT, Verstovsek S. New Therapies in Development for Myelofibrosis. Clin Lymphoma Myeloma Leuk. 20:(Suppl 1):S69-71, 2020. e-Pub 2020. PMID: 32862875.
5. Bose P, Verstovsek S. Mutational Profiling in Myelofibrosis: Implications for Management. Internat J Hematol 111(2):192-199, 2020. PMID: 31630335.
6. Economides MP, Verstovsek S, Pemmaraju N. Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors. Curr Hematol Malig Rep 14(5):460-468, 2019. PMID: 31372878.
7. Bose P, Verstovsek S. Updates in the Management of Polycythemia Vera and Essential Thrombocythemia. Therap. Advances Hematol 10(1):1-13, 2019. PMID: 31630335.
8. Bose P, Alfayez M, Verstovsek S. New Concepts of Treatment for Patients with Myelofibrosis. Curr Treat Options Oncol 20(1):5, 2019. PMID: 30675650.
9. Pettit K, Verstovsek S, Talpaz M. SOHO State-of-the-Art Updates and Next Questions: Myelofibrosis. Clin Lymphoma Myeloma Leuk 19(4):191-199, 2019. PMID: 30987952.
10. Masarova L, Bose P, Verstovsek S. The Rationale for Immunotherapy in Myeloproliferative Neoplasms. Curr Hematol Malig Rep 14(4):310-327, 2019. PMID: 31228096.
11. Bose P, Gotlib J, Harrison CN, Verstovsek S. SOHO State-of-the-Art Update and Next Questions: MPN. Clin Lymphoma Myeloma Leuk 18(1):1-12, 2018. PMID: 29277359.
12. Bose P, Verstovsek S. Management of Myelofibrosis-Related Cytopenias. Curr Hematol Malig Rep 13(3):164-172, 2018. PMID: 29796726.
13. Falchi L, Verstovsek S. KIT Mutations: New Insights and Diagnostic Value. Immunol Allergy Clin North Am 38(3):411-428, 2018. PMID: 30007460.
14. Bose P, Abou Zahr A, Verstovsek S. Investigational Janus Kinase Inhibitors in Development for Myelofibrosis. Expert Opin Investig Drugs 26(6):723-734, 2017. PMID: 28441920.
15. Bose P, Verstovsek S. Developmental Therapeutics in Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk 17S:S43-S52, 2017. PMID: 28760302.
16. Masarova L, Verstovsek S, Kantarjian H, Daver N. Immunotherapy-Based Approaches in Myelofibrosis. Expert Rev Hematol 10(10):903-914, 2017. PMID: 28799436.
17. Stein BL, Verstovsek S. Prognostication and Initiation of Therapy in Polycythemia Vera: Do We Have it Right?. Curr Hematol Malig Rep 12(6):507-509, 2017. PMID: 29032412.
18. Vaddi K, Verstovsek S, Kiladjian JJ. Ruxolitinib: A targeted treatment option for patients with Polycythemia Vera. Blood Lymphat Cancer 6:7-19, 2016. e-Pub 2016. PMID: 31360077.
19. Bose P, Verstovsek S. Prognosis of Primary Myelofibrosis in the Genomic Era. Clin Lymphoma Myeloma Leuk 16 Suppl:S105-13, 2016. PMID: 27521306.
20. Bose P, Verstovsek S. Myelofibrosis: An Update on Drug Therapy in 2016. Expert Opin Pharmacother 17(18):2375-2389, 2016. PMID: 27774820.
21. Bose P, Verstovsek S. Investigational Histone Deacetylase Inhibitors (HDACi) in Myeloproliferative Neoplasms. Expert Opin Investig Drugs 25(12):1393-1403, 2016. PMID: 27756180.
22. Bose P, Verstovsek S. Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management. J Natl Compr Canc Netw 14(12):1613-1624, 2016. PMID: 27956543.
23. Verstovsek S, Komrokji RS. Novel and emerging therapies for the treatment of Polycythemia Vera. Expert Rev Hematol 8(1):101-13, 2015. PMID: 25353086.
24. Falchi L, Verstovsek S. Eosinophilia in Hematologic Disorders. Immunol Allergy Clin North Am 35(3):439-52, 2015. PMID: 26209894.
25. Falchi L, Newberry KJ, Verstovsek S. New Therapeutic Approaches in Polycythemia Vera. Clin Lymphoma Myeloma Leuk 15 (Supplement):S27-33, 2015. PMID: 26297275.
26. Santos FP, Verstovsek S. Efficacy of Ruxolitinib for Myelofibrosis. Expert Opin Pharmacother 15(10):1465-73, 2014. PMID: 24856675.
27. Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Intern J General Medicine 7:89-101, 2014. e-Pub 2014. PMID: 24501543.
28. Santos FP, Verstovsek S. What is next beyond Janus kinase 2 inhibitors for primary myelofibrosis?. Curr Opin Hematol 20(2):123-9, 2013. PMID: 23385614.
29. Quintás-Cardama A, Verstovsek S. Molecular pathways: JAK/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res 19(8):1933-40, 2013. PMID: 23406773.
30. Tam CS, Verstovsek S. Investigational Janus Kinase Inhibitors. Expert Opin Investig Drugs 22(6):687-99, 2013. PMID: 23432430.
31. Santos FP, Verstovsek S. Therapy with JAK2 inhibitors for myeloproliferative neoplasms. Hematol Oncol Clin North Am 26(5):1083-99, 2012. PMID: 23009939.
32. Atallah E, Verstovsek S. Emerging drugs for myelofibrosis. Expert Opin Emerg Drugs 17(4):557-70, 2012. PMID: 23186315.
33. Komrokji R, Verstovsek S. Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition. Expert Rev Hematol 5(6):631-41, 2012. PMID: 23216593.
34. Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 10(2):127-40, 2011. PMID: 21283107.
35. Quintás-Cardama A, Verstovsek S. New JAK2 inhibitors for myeloproliferative neoplasms. Expert Opin Investig Drugs 20(7):961-72, 2011. PMID: 21521147.
36. Naqvi K, Verstovsek S, Kantarjian H, Ravandi F.. A potential role of ruxolitinib in leukemia. Expert Opin Investig Drugs 20(8):1159-66, 2011. PMID: 21635221.
37. Santos FP, Verstovsek S. JAK2 Inhibitors: Are They the Solution?. Clin Lymphoma Myeloma Leuk 11 Suppl 1(S28-36), 2011. PMID: 22035745.
38. Apostolidou E, Kantarjian HM, Verstovsek S. JAK2 inhibitors: A Reality? A Hope?. Clin Lymphoma Myeloma 9 (Suppl 3):S340-5, 2009. PMID: 19778862.
39. Atallah E, Verstovsek S. Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. Expert Rev Anticancer Ther 9(5):663-70, 2009. PMID: 19445582.
40. Verstovsek S. Therapeutic potential of JAK2 inhibitors. Hematology Am Soc Hematol Educ Program 1:636-642, 2009. PMID: 20008249.
41. Mesa RA, Quintás-Cardama A, Verstovsek S. Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia. Curr Hematol Malig Rep. 2(1):25-33, 2007. PMID: 20425385.
42. Verstovsek S, Quintás-Cardama A, Kantarjian H, Tefferi A. Experimental therapy in myelofibrosis with myeloid metaplasia. Expert Opin Investig Drugs 15(12):1555-63, 2006. PMID: 17107281.
43. Chifotides HT, Verstovsek S. Potential new therapeutic approaches for myelofibrosis. Clin Lymphoma Myeloma Leuk 21(Suppl. 1):S130-S134. e-Pub 2021.

Other Articles

1. Mughal TI, Pemmaraju N, Radich JP, Deininger MW, Kucine N, Kiladjian JJ, Bose P, Gotlib J, Valent P, Chen CC, Barbui T, Rampal R, Verstovsek S, Koschmieder S, Saglio G, Van Etten RA Emerging translational science discoveries, clonal approaches and treatment trends in chronic myeloproliferative neoplasms. Hematol Oncol 37(3):240-252, 2019. PMID: 31013548.
2. Masarova L, Verstovsek S Emerging drugs for essential thrombocythemia. Expert Opin Emerg Drugs 24(2):1-13, 2019. PMID: 31050912.
3. Masarova L, Verstovsek S The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis. Clin Adv Hematol Oncol 17(5):299-307, 2019. PMID: 31188809.
4. Boddu P, Carter BZ, Verstovsek S, Pemmaraju N SMAC mimetics as potential cancer therapeutics in myeloid malignancies. Br J Haematol 185(2):219-231, 2019. PMID: 30836448.
5. Bose P, Masarova L, Verstovsek S Novel Treatment Strategies for Myeloproliferative Neoplasms. Rinsho Ketsueki 60(9):1176-1185, 2019. PMID: 31597841.
6. Mughal TI, Lion T, Abdel-Wahab O, Mesa R, Scherber RM, Perrotti D, Mauro M, Verstovsek S, Saglio G, Van Etten RA, Kralovics R Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms. Hematol Oncol 36(5):740-748, 2018. PMID: 30074634.
7. Verstovsek S Highlights in myeloproliferative neoplasms from the 2017 American Society of Hematology Annual Meeting: Commentary. Clin Adv Hematol Oncol 16 Suppl 4(2):20-23, 2018. PMID: 29742090.
8. Verstovsek S, Fiskus W, Manshouri T, Bhalla KN Targeting cistrome and dysregulated transcriptome of post-MPN sAML. Oncotarget 8(55):93301-93302, 2017. PMID: 29212143.
9. Bose P, Verstovsek S Ruxolitinib for essential thrombocythemia?. Oncoscience 4(11-12):148-149, 2017. PMID: 29344542.
10. Kc D, Falchi L, Verstovsek S The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review. Ann Hematol 96(10):1595-1604, 2017. PMID: 28808761.
11. Falchi L, Kantarjian HM, Verstovsek S Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era. Leukemia 31(9):1845-1854, 2017. PMID: 28529308.
12. Bose P, Verstovsek S JAK2 inhibitors for myeloproliferative neoplasms: what is next?. Blood Rev 130(2):115-125, 2017. PMID: 28500170.
13. Assi R, Verstovsek S, Daver N 'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies. Curr Opin Hematol 24(2):115-124, 2017. PMID: 28072602.
14. Boddu P, Falchi L, Hosing C, Newberry K, Bose P, Verstovsek S The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review. Leuk Res 58:14-22, 2017. PMID: 28380402.
15. Falchi L, Bose P, Newberry KJ, Verstovsek S Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?. Br J Haematol 176(3):352-364, 2017. PMID: 27984634.
16. Bose P, Verstovsek S Myelofibrosis: an update on drug therapy in 2016. Expert Opin Pharmacother 17(18):1-15, 2016. PMID: 27774820.
17. Bose P, Verstovsek S Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management. J Natl Compr Canc Netw 14(12):1613-1624, 2016. PMID: 27956543.
18. Mesa RA, Komrokji RS, Verstovsek S Ruxolitinib dose management as a key to long-term treatment success. Int J Hematol 104(4):420-9, 2016. PMID: 27567907.
19. Ustun C, Arock M, Kluin-Nelemans HC, Reiter A, Sperr WR, George T, Horny HP, Hartmann K, Sotlar K, Damaj G, Hermine O, Verstovsek S, Metcalfe DD, Gotlib J, Akin C, Valent P Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. Haematologica 101(10):1133-1143, 2016. PMID: 27694501.
20. Verstovsek S Highlights in Polycythemia Vera from the 2016 EHA Congress. Clin Adv Hematol Oncol 14(10):810-813, 2016. PMID: 27930632.
21. Nazha A, Khoury JD, Verstovsek S, Daver N Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?. Crit Rev Oncol Hematol 105:112-7, 2016. PMID: 27401783.
22. Bose P, Verstovsek S Prognosis of Primary Myelofibrosis in the Genomic Era. Clin Lymphoma Myeloma Leuk 16 Suppl:S105-13, 2016. PMID: 27521306.
23. Bryan JC, Verstovsek S Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib. Cancer Chemother Pharmacol 77(6):1125-42, 2016. PMID: 27017614.
24. Zahr AA, Salama ME, Carreau N, Tremblay D, Verstovsek S, Mesa R, Hoffman R, Mascarenhas J Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica 101(6):660-71, 2016. PMID: 27252511.
25. Falchi L, Verstovsek S, Ravandi-Kashani F, Kantarjian HM The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy. Cancer 122(8):1160-8, 2016. PMID: 26716387.
26. Bose P, Verstovsek S The evolution and clinical relevance of prognostic classification systems in myelofibrosis. Cancer 122(5):681-92, 2016. PMID: 26717494.
27. Vaddi K, Verstovsek S, Kiladjian JJ. Ruxolitinib: a targeted treatment option for patients with Polycythemia Vera. Blood & Lymphat Cancer 6:7-19, 2016.
28. Kiladjian JJ, Winton EF, Talpaz M, Verstovsek S Ruxolitinib for the treatment of patients with polycythemia vera. Expert Rev Hematol 8(4):1-11, 2015. PMID: 25980454.
29. Falchi L, Verstovsek S Eosinophilia in Hematologic Disorders. Immunol Allergy Clin North Am 35(3):439-452, 2015. PMID: 26209894.
30. Kroll MH, Michaelis LC, Verstovsek S Mechanisms of thrombogenesis in polycythemia vera. Blood Rev 29(4):215-21, 2015. PMID: 25577686.
31. Gowin K, Verstovsek S, Daver N, Pemmaraju N, Valdez R, Kosiorek H, Dueck A, Mesa R Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis. Leuk Res 39(7):684-8, 2015. PMID: 25922307.
32. Falchi L, Newberry KJ, Verstovsek S New Therapeutic Approaches in Polycythemia Vera. Clin Lymphoma Myeloma Leuk 15 Suppl:S27-33, 2015. PMID: 26297275.
33. Verstovsek S New therapies for polycythemia vera. Clin Adv Hematol Oncol 13(6):356-8, 2015. PMID: 26352890.
34. Pozdnyakova O, Hasserjian RP, Verstovsek S, Orazi A Impact of Bone Marrow Pathology on the Clinical Management of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk 15(5):253-61, 2015. PMID: 25515354.
35. Benton CB, Tanaka M, Wilson C, Pierce S, Zhou L, Cortes J, Kantarjian H, Verstovsek S Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities. Leuk Res 39(4):419-23, 2015. PMID: 25687833.
36. Verstovsek S, Komrokji RS Novel and emerging therapies for the treatment of polycythemia vera. Expert Rev Hematol 8(1):1-13, 2015. PMID: 25353086.
37. Stein BL, Cervantes F, Giles F, Harrison CN, Verstovsek S Novel Therapies for Myelofibrosis. Leuk Lymphoma 56(10):1-30, 2015. PMID: 25860240.
38. Verstovsek S, Komrokji RS A comprehensive review of pacritinib in myelofibrosis. Future Oncol 11(20):2819-30, 2015. PMID: 26367195.
39. Arana Yi C, Tam CS, Verstovsek S Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis. Future Oncol 11(5):719-33, 2015. PMID: 25757677.
40. Sever M, Newberry KJ, Verstovsek S Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. Leuk Lymphoma - Review Article 55(12):2685-90, 2014. PMID: 24524340.
41. Yacoub A, Odenike O, Verstovsek S Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms. Curr Hematol Malig Rep 9(4):350-9, 2014. PMID: 25145552.
42. Gupta V, Gotlib J, Radich JP, Kröger NM, Rondelli D, Verstovsek S, Deeg HJ Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis. Biol Blood Marrow Transplant 20(9):1274-81, 2014. PMID: 24680977.
43. Santos FP, Verstovsek S Efficacy of ruxolitinib for myelofibrosis. Expert Opin Pharmacother 15(10):1465-73, 2014. PMID: 24856675.
44. Harrison C, Mesa R, Ross D, Mead A, Keohane C, Gotlib J, Verstovsek S Practical management of patients with myelofibrosis receiving ruxolitinib. Expert Rev Hematol 6(5):511-23, 2013. PMID: 24083419.
45. Verstovsek S, Almomen AK, Newberry K, Aleem A Development of ruxolitinib as a myelofibrosis therapy. Journal of Applied Hematology 4(3):89-95, 2013.
46. Quintás-Cardama A, Verstovsek S Molecular Pathways: JAK/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res 19(8):1933-40, 2013. PMID: 23406773.
47. Santos FP, Verstovsek S What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?. Curr Opin Hematol 20(2):123-9, 2013. PMID: 23385614.
48. Verstovsek S Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression. Eur J Haematol 90(2):89-98, 2013. PMID: 23181448.
49. Lee HJ, Daver N, Kantarjian HM, Verstovsek S, Ravandi F The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia. Clin Cancer Res 19(2):327-335, 2013. PMID: 23209034.
50. Verstovsek S Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis. Postgrad Med 125(1):128-35, 2013. PMID: 23391678.
51. Tam CS, Nazha A, Verstovsek S Pharmacotherapy of polycythemia vera. Expert Opinion Orphan Drugs 1(12):977-985, 2013.
52. Komrokji R, Verstovsek S Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition. Expert Rev Hematol 5(6):631-41, 2012. PMID: 23216593.
53. Atallah E, Verstovsek S Emerging drugs for myelofibrosis. Expert Opin Emerg Drugs 17(4):555-70, 2012. PMID: 23186315.
54. Santos FP, Verstovsek S JAK2 Inhibitors for Myelofibrosis: Why Are They Effective in Patients With and Without JAK2V617F Mutation?. Anticancer Agents Med Chem 12(9):1098-109, 2012. PMID: 22583424.
55. Santos FP, Verstovsek S Therapy with JAK2 Inhibitors for Myeloproliferative Neoplasms. Hematol Oncol Clin North Am 26(5):1083-99, 2012. PMID: 23009939.
56. Komrokji RS, Verstovsek S, Padron E, List AF Advances in the management of myelofibrosis. Cancer Control 19(4 Suppl):4-15, 2012. PMID: 23042420.
57. Verstovsek S Development and Clinical Use of a New Therapy for Myelofibrosis: Oral Ruxolitinib. Treatment Strategies – Hematology 2(2):61-65, 2012.
58. Quintás-Cardama A, Verstovsek S Spleen deflation and beyond: The pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms. Cancer 118(4):870-7, 2012. PMID: 21766300.
59. Ostojic A, Vrhovac R, Verstovsek S Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Ther Clin Risk Manag 8:95-103, 2012. PMID: 22399854.
60. Mascarenhas J, Mughal TI, Verstovsek S Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib. Curr Med Chem 19(29):4399-413, 2012. PMID: 22830345.
61. Randhawa J, Ostojic A, Vrhovac R, Atallah E, Verstovsek S Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. J Hematol Oncol 5(1):43, 2012. PMID: 22852872.
62. Quintás-Cardama A, Jain N, Verstovsek S Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis. Cancer 117(24):5439-49, 2011. PMID: 21692073.
63. Ostojic A, Vrhovac R, Verstovsek S Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis. Future Oncol 7(9):1035-43, 2011. PMID: 21919691.
64. Santos FP, Verstovsek S JAK2 Inhibitors: Are They the Solution?. Clin Lymphoma Myeloma Leuk 11 Suppl 1:S28-36, 2011. PMID: 22035745.
65. Santos FP, Verstovsek S JAK2 inhibitors: What's the true therapeutic potential?. Blood Rev 25(2):53-63, 2011. PMID: 21095048.
66. Agrawal M, Garg RJ, Cortes J, Kantarjian H, Verstovsek S, Quintas-Cardama A Experimental therapeutics for patients with myeloproliferative neoplasias. Cancer 117(4):662-76, 2011. PMID: 20922795.
67. Verstovsek S Therapeutic Potential of Janus-activated Kinase-2 Inhibitors for the Management of Myelofibrosis. Clin Cancer Res 16(7):1988-96, 2010. PMID: 20215535.
68. Verstovsek S Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders. Leuk Res 33(5):617-23, 2009. PMID: 19013641.
69. Atallah E, Verstovsek S Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. Expert Rev Anticancer Ther 9(5):663-70, 2009. PMID: 19445582.

Abstracts

1. Verstovsek S, Kuykendall A, Hoffman R, Koschmieder S, Passamonti F, Valone F, Modi NB, Khanna S, O'Connor PG, Gupta SK, Kiladjian J-J. VERIFY: A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera. Blood 140(Suppl. 1), abstract #1709, 2022. e-Pub 2022.
2. Verstovsek S, Oh ST, Kiladjian J-J, Platzbecker U, Passamonti F, Gerds AT, Vannucchi AM, McLornan DP, Gupta V, Grosicki S, Haifa Kathrin Al-Ali H, Lavie D, Kuykendall A, Lee S-E, Iurlo A, Ocroteala L, Kawashima J, Donahue R, Strouse B, Mesa R. Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from MOMENTUM. Blood 140(Suppl. 1), abstract #3028:6803-6805, 2022. e-Pub 2022.
3. Verstovsek S, Yu J, Bland E, Schuler T, Cordaro T, Braunstein E. Real-World Use of Ruxolitinib in Patients with Myelofibrosis Who Had Anemia or Thrombocytopenia at US Community Practices. Blood 140(Suppl. 1), abstract #3630, 2022. e-Pub 2022.
4. Gerds AT, Mesa R, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall A, Grosicki S, Iurlo A, Goh YT Lazaroiu M, Egyed M, Fox ML, McLornan DP, Perkins AC, Yoon S-S, Gupta V, Kiladjian J-J, Rafe Donahue R, Kawashima J, Verstovsek S. Updated Results from the MOMENTUM Phase 3 Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor. Blood 140(Suppl. 1), abstract #627, 2022. e-Pub 2022.
5. Masarova L, Bose P, Pemmaraju N, Richie MA, Borthakur G, Estrov ZE, Kantarjian H, Patel KP, Verstovsek S. Long Term Results of Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocythemia and Polycythemia Vera: Median Follow-up of 15 Years. Blood 140(Suppl. 1), abstract #4353, 2022. e-Pub 2022.
6. Mascarenhas J, Kremyanskaya M, Patriarca A, Harrison C, Bose P, Rampal RK, Palandri F, Devos T, Passamonti F, Hobbs G, Talpaz M, Vannucchi A, Kiladjian JJ, Verstovsek S, Hoffman R, Salama ME, Chen D, Taverna P, Chang A, Colak G, Klein S, Gupta V. MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S335-S336, 2022. PMID: 36164005.
7. Mesa R, Gerds A, Vannucchi A, Al-Ali HK, Lavie D, Kuykendall A, Grosicki S, Iurlo A, Goh YT, Lazaroiu M, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Donahue R, Kawashima J, Verstovsek S. MPN-478 MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S339-S340, 2022. PMID: 36164012.
8. Gerds A, Verstovsek S, Vannucchi A, Al-Ali HK, Lavie D, Kuykendall A, Grosicki S, Iurlo A, Goh YT, Lazaroiu M, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Donahue R, Kawashima J, Mesa R. MPN-483 Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM]. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S340, 2022. PMID: 36164014.
9. Mesa R, Komatsu N, Gill H, Jin J, Lee SE, Hou HA, Sato T, Qin A, Urbanski R, Shih W, Zagrijtschuk O, Zimmerman C, Verstovsek S. MPN-545 SURPASS-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as Second Line Therapy in Essential Thrombocythemia. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S342, 2022. PMID: 36164019.
10. Oh S, Mesa R, Harrison C, Bose P, Gerds A, Gupta V, Swami A, Tyavanagimatt S, Buckley S, Roman-Torres K, Verstovsek S. MPN-145 Retrospective Analysis of Anemia Benefit of Pacritinib From the PERSIST-2 Trial. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S327, 2022. PMID: 36163989.
11. Verstovsek S, Salama ME, Mascarenhas J, Talpaz M, Mesa RA, Vannucchi A, Rampal R, Oh ST, Olteanu H, Chiu A, Chen D, Hanson CA, Curto-Garcia N, Taverna P, Cui J, Zavidij O, Chen Z, Colak G, Efuni S, Keller PJ, Trojer P, Harrison CN. Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis – Preliminary Data. Blood 138 (Suppl. 1):2568, 2021. e-Pub 2021.
12. Verstovsek S, Kuykendall AT, Hoffman R, Ginzburg Y, Pemmaraju N, Valone F, Modi NB, Khanna S, O'Connor PG, Gupta SK, Kiladjian J-J. A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera. Blood 138 (Suppl. 1):1504, 2021. e-Pub 2021.
13. Oh ST, Gerds AT, Mesa RA, Gupta V, Huang M, Ro S, Strouse B, Klencke BJ, Verstovsek S. Baseline Serum Ferritin Differentially Predicts W24 Transfusion Independence Response for Momelotinib and Ruxolitinib in Patients with Myelofibrosis. Blood 138 (Suppl. 1):3638, 2021. e-Pub 2021.
14. Verstovsek S, Kiladjian J-J, Vannucchi AM, Scherber R, Hamer-Maansson JE, Harrison CN. Does Early Intervention in Myelofibrosis Impact Outcomes? A Pooled Analysis of the COMFORT-I and -II Studies. Blood 138(Suppl. 1):1505, 2021. e-Pub 2021.
15. Verstovsek S, Al-Ali HK, Mascarenhas J, Mead AJ, Perkins A, Vannucchi AM, Uyei A, Rothbaum WP, McGreivy J, Kiladjian J-J. BOREAS: A global phase 3 study of KRT-232, a first-in-class murine double minute 2 (MDM2) inhibitor in TP53^WT relapsed/refractory (R/R) myelofibrosis (MF). J. Clin. Oncol 39(Suppl. 15):abstract TPS7057, 2021. e-Pub 2021.
16. Mesa RA, Oh ST, Gerds AT, Gupta V, Catalano JV, Cervantes F, Devos T, Hus M, Kiladjian J-J, Lech-Maranda E, Mclornan DP, Palmer J, Platzbecker U, Treliński J, Shimoda K, Donahue R, Strouse B, Kowalski MM, Verstovsek S. Association of transfusion independence with improved overall survival in myelofibrosis patients receiving momelotinib. J. Clin. Oncol 39(Suppl. 15):abstract 7046, 2021. e-Pub 2021.
17. Verstovsek S, Yu J, Scherber RM, Pandya S, Dieyi C, Chen CC, Parasuraman S. Changes in the Incidence and Overall Survival of Patients with Myeloproliferative Neoplasms between 2002 and 2016 in the United States. Blood 136(Suppl. 1):12-13, 2020. e-Pub 2020.

Book Chapters

1. Bose P, Masarova L, Amin HM, Verstovsek S. Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. In: The MD Anderson Manual of Medical Oncology. 4^th Edition. McGraw Hill: China, 119-162, 2022.
2. Pasca S,* Chifotides HT,* Verstovsek S, Bose P. Mutational Landscape of Blast Phase Myeloproliferative Neoplasms (MPN-BP) and Antecedent MPN. In: Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part B, Vol. 366, In the Book Series: International Review of Cell and Molecular Biology, Bartalucci N, Ed., Academic Press, [*the 2 authors share first authorship]. 1^st Edition, 83-124, 2022.
3. Bose P, Verstovsek S. Polycythemia Vera. In: BMJ Best Practice. BMJ: Publishing Group: London, 2021.
4. Komrokji R, Kuykendall A, Padron E, Verstovsek S. Myelofibrosis. In: Wintrobe's Clinical Hematology. 14^th Edition. Wolters Kluwer: China, 1768-1781, 2018.
5. Verstovsek S, Akin C. Mastocytosis. In: Encyclopedia of Cancer. 4^th Edition. Springer-Verlag Berlin Heidelberg, 2668-2672, 2017.
6. Bose P, Verstovsek S. Polycythemia Vera 2016 Update. In: BMJ Best Practice. BMJ Publishing Group: London, 2016.
7. Verstovsek S, Newberry KJ, Amin HM. Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (Chapter 6). In: The MD Anderson Manual of Medical Oncology. 3^rd Edition. McGraw-Hill Education, 103-130, 2016.
8. Falchi L, Verstovsek S. Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment (Chapter 10). In: Managing Myeloproliferative Neoplasms: A Case-Based Approach. Cambridge University Press: United Kingdom, 79-85, 2016.
9. Verstovsek S, Newberry K. JAK inhibitors as therapy for myelofibrosis. In: Novel Insights into Myelofibrosis Pathophysiology and Treatment. Future Medicine Ltd: London, 104-122, 2015.
10. Santos FPS, Verstovsek S. Myelofibrosis. In: Clinical Oncology News Essential Oncology, 2015.
11. Tam CS, Verstovsek S. Polycythemia Vera. In: Clinical Oncology News Essential Oncology, 2015.
12. Tam CS, Verstovsek S. Polycythemia Vera (Chapter 24). In: Cancer Consult: Expertise for Clinical Practice. 1^st Edition. Wiley-Blackwell: New Jersey, 152-155, 2014.
13. Santos FPS, Verstovsek S. JAK Inhibitor Therapy for Patients with Myeloproliferative Neoplasms. In: Myeloproliferative Neoplasms: Clinician's Guide for AppleiOS (Version 8.1). Go2 Network LLC, 2014.
14. Santos FPS, Verstovsek S. Ongoing Clinical Trials in Myeloproliferative Neoplasms. In: Myeloproliferative Neoplasms, Critical Concepts and Management. Springer-Verlag Berlin Heidelberg, 215-232, 2012.
15. Santos F, Verstovsek S. JAK2 Inhibitors for Therapy of Myeloproliferative Neoplasms. In: Myeloproliferative Neoplasms Biology and Therapy. Book Series: Contemporary Hematology. Humana Press: London, 151-167, 2011.
16. Mesa R, Verstovsek S. Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. In: Leukemias: Principles and Practice of Therapy. Wiley-Blackwell Publishing Ltd, 362-372, 2011.
17. Jain N, Amin HM, Verstovsek S. Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. In: The MD Anderson Manual of Medical Oncology. 2^nd Edition. McGraw-Hill: New York, 97-121, 2011.
18. Santos FPS, Verstovsek S. Myelofibrosis. In: Leukemia: Emerging Cancer Therapeutics. 2^nd Edition. Demos Medical Publishing: New York, 307-328, 2011.
19. Verstovsek S, Akin C. Mastocytosis. In: Encyclopedia of Cancer. 3^rd Edition. Springer-Verlag Berlin Heidelberg, 2178-2182, 2011.
20. Verstovsek S, Akin C. Mastocytosis. In: Encyclopedia of Cancer. 2^nd Edition. Springer-Verlag Berlin Heidelberg, 1779-1783, 2009.
21. Verstovsek S. Therapeutic potential of JAK2 inhibitors. In: American Society Hematology Educational Program, 636-642, 2009.
22. Verstovsek S, El-Ahdab SY, Amin HM. Other Myeloproliferative Disorders. In: Atlas of Cancer. 2^nd Edition. Springer, 334-344, 2008.
23. Verstovsek S, Cortes J.. Chronic idiopathic myelofibrosis. In: BCR/ABL-Negative Chronic Myeloproliferative Disorders. 1^st Edition. Informa Healthcare, CRC Press, 182-194, 2008.
24. Verstovsek S, Mesa R. New Drugs in Myeloproliferative Disorders. In: Myeloproliferative Disorders: Biology and Management. 1^st Edition. Taylor and Francis, 143-160, 2007.
25. Mihich E, Maccubbin D, Pocchiari S, Ujhazy P, Verstovsek S, Ehrke MJ. Immunoregulation by tumor necrosis factor (TNF): An opportunity for therapeutic intervention. In: Cancer Treatment An Update. Springer-Verlag: Paris, 759-764, 1994.